Here, we summarize the results or design of clinical studies recently completed or initiated to evaluate the therapeutic activity of chloroquine derivatives in cancer patients.


Here, we summarize the results or design of clinical studies recently completed or initiated to evaluate the therapeutic activity of chloroquine derivatives in cancer patients.

HCQ reduces lipopolysaccharide/TLR-mediated immune activation; this compound could be a useful immunomodulant in HIV-infected patients.

Source: PLOS Pathogens Author: Aartjan J. W. te Velthuis,Sjoerd H. E. van den Worm,Amy C. Sims,Ralph S. Baric,Eric J. Snijder ,Martijn J. van Hemert Abstract Increasing the intracellular Zn2+ concentration with zinc-ionophores like pyrithione (PT) can efficiently impair the replication of a variety of RNA viruses, including poliovirus and influenza virus. For some viruses this effect has […]

The anti-HIV effect of chloroquine/hydroxychloroquine is modest by itself but is additive or synergistic when combined with selected antiretrovirals.